EBMT 2019 | A consensus grading system for toxicities in CAR T trials
A new grading system for use in chimeric antigen receptor (CAR) T-cell trials was presented on Tuesday 26 March 2019, during the 45th Meeting of the EBMT
A new grading system for use in chimeric antigen receptor (CAR) T-cell trials was presented on Tuesday 26 March 2019, during the 45th Meeting of the EBMT
Here, we summarize the 4-year follow-up data from the phase III GLOW trial investigating fixed duration ibrutinib + venetoclax vs chlorambucil + obinutuzumab in previously…
Here, we summarize the results of the phase II TARMAC trial, published by Minson et al.1 in Blood, of the combination of time-limited ibrutinib and…
On March 14, 2024, the U.S. FDA approved lisocabtagene maraleucel, a CD19-directed CAR T-cell therapy, for the treatment of adult patients with R/R CLL/SLL.
Here, we summarize the 6-year follow-up and subgroup analyses from the M13-982 trial that assessed venetoclax monotherapy in patients aged ≥18 years with R/R or…
The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive
We summarize a presentation of real-world data on tocilizumab for the management of CAR T-cell-associated cytokine release syndrome shared by Delaney at the EBMT-EHA 6th…
Following positive response data from the phase II ROSEWOOD study, zanubrutinib plus obinutuzumab receives accelerated U.S. FDA approval for the treatment of adult patients with…
Here, we summarize an article on the outcomes of subsequent therapies after 2L axi-cel or SOC treatment in patients with R/R LBCL in the ZUMA-7…
Indapta Therapeutics, Inc., a privately held biotechnology company developing next-generation differentiated cell therapies for the treatment of cance
Indapta Therapeutics, Inc., a privately held biotechnology company developing next-generation differentiated cell therapies for the treatment of cance